Intellia Therapeutics

Many of us pursuing work in the biotechnology industry are inspired by a loved one who is living with a disease or the loss of someone in our community. Rare genetic and oncological and immunological diseases not only affect the people living with often debilitating and life-threatening symptoms, but these disorders also significantly impact their families, friends and caregivers.

Our researchers work tirelessly to harness the genome editing technology CRISPR/Cas9 for human therapeutic use. Jennifer Doudna, an Intellia co-founder, and Emmanuelle Charpentier were awarded the 2020 Nobel Prize in Chemistry for their pioneering work in CRISPR. We at Intellia are humbled to have a hand in making what we believe to be medical history. As a leader in this space, we take this responsibility to patients seriously.

We are employing a modular genome editing platform to create diverse in vivo and ex vivo pipelines, spanning a range of therapeutic indications. Guided by this full-spectrum approach, we are committed to making CRISPR/Cas9-based medicines a reality for patients suffering from genetic diseases and to creating novel engineered cell therapies for various cancers and autoimmune diseases.

Change life stories with genome editing therapies!

AWARDS
  • 2025 BPTW Badge - RBG.png
  • 2024 Best Places to Work
  • 2023 Best Places to Work
  • Intellia Top places to work
  • 2022 Best Places to Work
  • Intellia 2022 BG top places
40 Erie Street
Cambridge, MA 02139
Stock Symbol: NTLA
  • Featured Employer
At Intellia, we are revolutionizing medicine by harnessing the power of genome editing to develop CRISPR one-time treatments.
Tune into our podcast, Imagine the Possibilities, where we showcase Intellia talent across departments and take deep dives into all things culture and careers. We talk about career steps (and missteps), development, growth, and more. Just imagine the possibilities of what we can learn together.
Employee Testimonials
  • “Diversity, Equity and Inclusion is really important to me because in order to deliver our drugs to patients and achieve our goals, we need to create a work environment where everybody – regardless of race, gender, or sexuality – can come to Intellia and succeed here. That is what the Employee Resource Groups do, and that is why it is so important that Intellia has this program.”
    Peter C. Associate Scientist
  • “I lead the Community, Wellness, and Sustainability Cultural Ambassadors Team and am deeply passionate about the environment and wellness from a holistic point of view. As a team, we raise awareness on topics like plastic pollution, sustainable living, and climate change. We motivate others to adopt simple, yet impactful adjustments to their lifestyle and promote healthy work-life balance by offering weekly practices such as yoga, mindfulness and meditation.”
    Elena K, Sr Scientist, RNA Chemistry & Delivery Sciences
  • “There have been an immense number of opportunities for me to step up and make meaningful contributions to Intellia’s vision. I’ve been surrounded by career role models thoughout my time here. I learn from their career growth and apply those learnings to my own journey.”
    Ramsey M, Director, Delivery Sciences, Delivery Physics, and Biology
NEWS
Job descriptions are the candidate’s first impression of a company. And if that introduction includes exclusionary language, they’re less likely to apply even if they are the perfect fit for the job.
Intellia Therapeutics and Regeneron Pharmaceuticals presented positive interim data from an ongoing Phase I trial of NTLA-2001 for transthyretin (ATTR) amyloidosis.
Intellia’s first-quarter financial conference call and report focused on the ongoing Phase I trial of NTLA-2001 in transthyretin (ATTR) amyloidosis with polyneuropathy patients.
Carver Biosciences is developing next-generation gene editing technology using Cas13. By editing RNA, this method makes it possible to target and then edit or destroy RNA from viruses like SARS-CoV-2.
Denali initiates dosing in Phase I/II frontotemporal dementia study. Intellia snags Orphan Drug Designation for experimental T cell receptor (TCR)-T cell therapy, NTLA-5001 in AML.
The biopharma industry ended February and began March with plenty of clinical trial news. BioSpace shares the highlights.
The U.S. Patent and Trademark Office ruled that the use of CRISPR-Cas9 in humans belongs to Broad, not UC Berkeley.
AstraZeneca and Neurimmune have signed an exclusive global collaboration and licensing deal to develop, manufacture and commercialize NI006 for ATTR-CM.
Positive interim data from the global Phase I trial of single-dose NTLA-2001 demonstrated a mean serum TTR reduction of 93% at the highest dose level of 1.0 mg/kg by day 28.
JOBS
  • Intellia 2025 Premier
  • Intellia 2024 Elite artwork
IN THE PRESS